Find a Clinical Trial

The purpose of this research is to offer patients with centrally located early-stage non-small cell lung cancer (NSCLC) who are NOT candidates for surgery the opportunity to receive stereotactic body radiation therapy (SBRT).

Tozorakimab is hypothesized to have a beneficial effect in patients with COPD by reducing the frequency and severity of COPD exacerbations and improving COPD symptoms and quality of life.

This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 versus placebo on top of standard of care in participants with PPF over 52 weeks. Up to 300 eligible participants will be randomized to 1 of 3 treatment arms: AP01 high dose, AP01 low dose, or placebo.

The current study will test the feasibility of using an engineering-inspired study design to identify effective COPD self-management treatment components.

A Study of Amivantamab in Participants with Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

A Study of Lazertinib and Amivantamab in Participants with Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer.

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 subjects with KRASG12C mutant NSCLC that have not been exposed to prior therapy with KRASG12C inhibitors and/or SHP2 inhibitors.

RELIANCE is multi-site pragmatic study to compare long-term roflumilast use with long-term azithromycin use in people who have COPD with chronic bronchitis who have been hospitalized in the past year.

We are looking for people with chronic obstructive pulmonary disease (COPD) who need to improve their disease control further. RESOLUTE is a study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils. Eosinophils are a type of blood cell that helps the body to fight infections and is involved in inflammation, immune and allergic reactions. Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count.

The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis.